MedTrace Logo

Phase II Study in Patients With Operable Breast Cancer

NCT00518583 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-01-15

No results posted yet for this study

Summary

The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.

Conditions

Interventions

DRUG

Pegylated Liposomal Doxorubicin (Doxil)

Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly

Sponsors & Collaborators

  • Ortho Biotech Products, L.P.

    collaborator INDUSTRY

  • Aptium Oncology Research Network

    lead NETWORK

Principal Investigators

  • John Macdonald, MD · CMO Aptium Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-01-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518583 on ClinicalTrials.gov